What the research shows about Banaba Leaf and corosolic acid, the mechanism behind its glucose effects, and how Banaba fits into GlycoCare.
By Dr. Nathan Riley, MD · Published April 12, 2026 · Updated April 24, 2026
Banaba Leaf is one of the less familiar ingredients in Western supplement shelves but one of the most established blood sugar botanicals in Southeast Asian traditional medicine. Grown in the Philippines, Indonesia, southern China, and India, the tree Lagerstroemia speciosa has been used for centuries as a tea made from its leaves for what traditional practitioners described as sugar disease. Modern research has focused on a specific compound isolated from these leaves: corosolic acid.
This article reviews the research on corosolic acid and Banaba Leaf extract, clinical dosing, mechanism of action, who is likely to benefit, safety considerations, and how Banaba Leaf fits into the GlycoCare formulation.
The Banaba tree is a flowering hardwood native to tropical Asia. Traditional Filipino medicine used a tea brewed from the young leaves and fruits for a wide range of purposes, most consistently documented for conditions that would correspond to what we now recognise as elevated blood glucose and metabolic dysfunction. The traditional preparation was simple: dried leaves steeped in hot water, consumed daily.
Pharmacological interest in Banaba accelerated in the late twentieth century when Japanese researchers isolated corosolic acid from the leaves and documented its glucose-lowering activity in animal models. Commercial extracts standardised to corosolic acid content have since become widely available, particularly in blood sugar-focused supplement formulations.
Corosolic acid is a pentacyclic triterpenoid — a class of plant compounds that also includes ursolic acid and oleanolic acid from other botanical sources. Its action on glucose metabolism appears to involve several mechanisms that work in parallel:
GLUT4 translocation support. Corosolic acid appears to promote the translocation of GLUT4 — the primary insulin-responsive glucose transporter — from intracellular vesicles to the cell surface in muscle and fat tissue. This is similar in mechanism to the effect that insulin itself produces, though through a partially independent signalling pathway.
Mild alpha-glucosidase inhibition. Corosolic acid also shows modest alpha-glucosidase inhibiting activity, similar in direction (though weaker) to White Mulberry Leaf. The combined effect is a gentler rise in blood glucose after carbohydrate-containing meals.
Potential effects on adipocyte metabolism. Preliminary research has also explored whether corosolic acid affects lipid storage and adipogenesis, which could have relevance for the metabolic dimension of blood sugar dysregulation. The evidence here is earlier-stage than the glucose work.
Human clinical trials on Banaba Leaf extract standardised to corosolic acid have been smaller in number than those for Gymnema or cinnamon but have generally produced positive results in the expected direction. Trials in adults with type 2 diabetes have reported modest reductions in fasting glucose and post-meal glucose peaks after 30 to 60 days of daily supplementation.
Trials in adults with impaired glucose tolerance (a prediabetic range) have produced similar directional effects, though the magnitude has been smaller and less consistently significant. In healthy adults with normal glucose tolerance, effects have been difficult to demonstrate, which is consistent with the general pattern for blood sugar ingredients: they tend to produce clearer effects when there is a meaningful dysregulation to correct.
The National Center for Complementary and Integrative Health maintains general summaries of botanical supplement research. Primary research is searchable on PubMed under terms like "banaba corosolic acid glucose."
Clinical research doses of Banaba Leaf extract have ranged from 16 mg to 48 mg of corosolic acid daily, typically delivered as a standardised extract where the extract weight is larger than the corosolic acid content. A common commercial standardisation is Banaba extract delivering 1% to 2% corosolic acid, meaning 250 mg of extract at 1% standardisation delivers 2.5 mg of corosolic acid.
This makes standardisation labelling particularly important for Banaba. A product listing "Banaba Leaf Extract 100 mg" without specifying standardisation could theoretically deliver anywhere from less than 1 mg to around 20 mg of the active compound depending on the extract. GlycoCare lists Banaba Leaf among its ingredients; clearer labelling of corosolic acid content would meaningfully improve transparency.
Banaba Leaf is generally well tolerated. Reported side effects are rare and usually mild, with occasional digestive adjustment or headache in early use. Long-term safety studies are less extensive than for some other blood sugar botanicals, which argues for the standard recommendation not to exceed published clinical trial doses.
The most important interaction consideration is with antidiabetic medications. Banaba can additively lower blood glucose when combined with insulin, sulfonylureas, or other glucose-lowering drugs. Anyone on these medications should discuss supplement use with the prescribing clinician, who may wish to adjust dosing and monitor blood glucose more frequently during the adjustment window.
As with most blood sugar botanicals, Banaba should be avoided during pregnancy and breastfeeding due to insufficient safety data, and should be discontinued at least two weeks before any planned surgery because of its glucose-affecting activity.
Banaba Leaf in the GlycoCare formulation sits alongside Gymnema Sylvestre, Bitter Melon, Cinnamon Bark, and White Mulberry Leaf in the botanical glucose utilisation pathway. Among these five, Banaba's mechanism is unique in its mild support of GLUT4 translocation, which gives it a partially distinct contribution to the overall formula rather than simply duplicating the effects of the other botanicals.
For a daily-use, multi-ingredient formula aimed at healthy adults seeking metabolic maintenance, this combination-based approach is reasonable. For adults with significant insulin resistance or type 2 diabetes, a higher-dose single-ingredient Banaba supplement taken under medical supervision would deliver a more targeted effect at a higher per-ingredient dose.
Banaba Leaf is a well-established blood sugar botanical with a specific pharmacology centred on corosolic acid. Clinical research is less voluminous than for cinnamon or chromium but broadly positive in direction. Standardisation to corosolic acid percentage is the single most useful label specification, and a gap in many commercial products including GlycoCare. Within a twelve-ingredient formula, Banaba contributes meaningfully to the multi-pathway approach. For anyone on antidiabetic medication, the coordination conversation with the prescribing clinician is important.
This article is for educational purposes only and is not medical advice. Always consult your physician before starting any supplement, particularly if you have diabetes, prediabetes, hypoglycemia, or take any prescription medication for blood sugar control. Individual response varies. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. Statements have not been evaluated by the FDA.